Rahman Alif Noeriyanto, Herman Herry, Kriswanto Eri, Faried Ahmad, Nasser Mochammad Kamal
Musculoskeletal Pain Intervention and Regeneration, Faculty of Medicine Universitas Padjadjaran, Orthopaedic and Pain Intervention Center of Sentra Medika Hospital, Depok, Indonesia.
Pain Intervention and Regeneration, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.
J Pain Res. 2022 Jul 15;15:1983-1993. doi: 10.2147/JPR.S357284. eCollection 2022.
Knee osteoarthritis (OA) is a chronic and progressive degenerative disease. It resulted from mechanical and chemical disorders that damage the joint and the underlying bone. The management of knee OA is challenging due to poor self-regeneration of connective tissues. Surgical treatment with prolotherapy approaches was conducted to treat medial compartment knee OA.
To know the injection frequency to reach a 50% improvement in VAS score and WOMAC index.
Six patients who suffered from late-stage medial compartment knee OA underwent PFO followed by twelve sessions of intra-articular dextrose prolotherapy. The subjective pain score, visual analog scale (VAS), was assessed based on the patient subjectiveness before and after treatment. Patients marked the score from 0 to 10 cm to describe the current pain state. The functional index, the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index used to evaluate the Patient's clinical symptoms. It ranges from 0 to 96 points consisting of three main sections: pain (total 20 points), stiffness (total: eight points), and physical function disability (total 68 points). Higher scores indicate severe symptoms and function.
Four patients showed pain relief and functional improvement with more than 50% scores of VAS and WOMAC after the treatment. Two patients received more than twelve doses of intra-articular dextrose prolotherapy due to a lack of progress.
This study provides clinical evidence for a new treatment strategy for advanced knee OA. This combined therapy improves the patient's daily activity function and postpones the need for total knee arthroplasty (TKA).
膝关节骨关节炎(OA)是一种慢性进行性退行性疾病。它由机械和化学紊乱导致,这些紊乱会损害关节及下方骨骼。由于结缔组织自我修复能力差,膝关节OA的治疗具有挑战性。采用注射疗法进行手术治疗以治疗膝关节内侧间室OA。
了解达到视觉模拟评分(VAS)和西安大略和麦克马斯特大学骨关节炎指数(WOMAC)改善50%所需的注射频率。
六名患有晚期膝关节内侧间室OA的患者接受了经皮纤维环成形术(PFO),随后进行了12次关节内葡萄糖注射疗法。根据患者治疗前后的主观感受评估主观疼痛评分,即视觉模拟量表(VAS)。患者从0到10厘米标记分数以描述当前疼痛状态。功能指数,即西安大略和麦克马斯特大学骨关节炎(WOMAC)指数用于评估患者的临床症状。其范围为0至96分,由三个主要部分组成:疼痛(共20分)、僵硬(共8分)和身体功能障碍(共68分)。分数越高表明症状和功能越严重。
四名患者在治疗后VAS和WOMAC评分改善超过50%,显示出疼痛缓解和功能改善。两名患者由于缺乏进展接受了超过12剂的关节内葡萄糖注射疗法。
本研究为晚期膝关节OA的新治疗策略提供了临床证据。这种联合疗法改善了患者的日常活动功能,并推迟了全膝关节置换术(TKA)的需求。